

ABSTRACT

Novel recombinant antibodies from murine antibody IOR C5 produced by the
hybridoma deposited with the ECCC 97061101. ^{The} Said recombinant antibodies were
obtained using recombinant DNA technology and are characterized in that they
recognize antigen ior C2. The recombinant antibodies are specifically chimeric
antibody, humanized antibody, and single chain Fv fragment. The chimeric antibody
contains the variable domains of the murine immunoglobuline and the constant
regions of the human immunoglobuline. The humanized antibody contains the
constant regions of human immunoglobuline and has been specifically modified in
the murine frameworks regions (FRs) and within the latter, in those areas that may
result in an antigenic site for cells T. The Fv fragment contains the variable domains
of murine immunoglobuline. The invention also relates to the utilization of
recombinant antibodies derived from murine antibody ior C5 in the diagnosis and
therapy of colorectal tumors, the metastasis thereof and recurrences.

1
3/05
LEN